EASTERN COOPERATIVE ONCOLOGY GROUP

约翰霍普金斯大学自1955年以来一直是ECOG的成员。我们的主要目标是将约翰霍普金斯大学试点的创新临床研究方案和实验室相关研究带到ECOG进一步发展。与此同时，我们作为方案研究主席、疾病和模式导向委员会主席提供领导，并在成员层面广泛参与委员会。在此拨款续期期间的具体目标是：(1)继续在以疾病为导向的委员会中提供科学领导：肺、头颈、乳腺、病理学、脑肿瘤、艾滋病恶性肿瘤，并将这些努力扩大到GU、白血病、淋巴瘤和骨髓瘤。(2)将转化研究、细胞生物学和分子生物学纳入疾病各个阶段的临床方案，包括预防；(3)扩大应计收益；(4)增加附属社区医院的参与。我们期望通过我们的教师在获得资助的实验室科学和临床研究补助金方面的成功努力来实现这些目标，例如肺癌，前列腺癌和胰腺癌的SPORE补助金以及我们与NCI的持续一期合同。这些资助将允许开展I期临床试验，包括一次骨髓移植、基因疗法和新型细胞毒性药物，然后可以带到ECOG进行特定疾病的II期和III期评估。约翰霍普金斯大学参与ECOG的新领域包括泌尿生殖系统和血液系统恶性肿瘤。将这两个领域的创新研究项目引入ECOG的机制已经到位。由于我们计划在约翰霍普金斯大学建立一个新的更大的癌症中心，临床项目和教职员工的扩大，预计利润会增加。此外，我们还任命了一名新的区域项目主任，他的具体目标是扩大我们的医院网络，使更多的人能够获得ECOG/NCI赞助的高优先级试验，包括癌症控制和预防研究。

Johns Hopkins has been a member of ECOG since 1955. Our primary goal is to bring innovative clinic research protocols and laboratory correlative studies piloted at Johns Hopkins to ECOG for further development. In conjunction with this, we provide leadership as protocol study chairs, disease and modality oriented committee chairs, as well as wide committee participation at the membership level. The specific aims during this grant renewal period are to: (1) continue to provide scientific leadership in the disease oriented committees: Lung, Head and Neck, Breast, Pathology, Brain Tumors, AIDS malignancies and to expand these efforts into GU, leukemia, lymphoma and myeloma. (2) to bring translational research, cell biology and molecular biology into clinical protocols for all stages of disease including prevention; (3) to expand our accrual; (4) to increase participation of our affiliated community hospitals. We expect to achieve these aims through the successful efforts of our faculty in obtaining funded laboratory science and clinical research grants such as the SPORE grants in lung, prostate and pancreatic cancer and our continuing Phase I Contract with the NCI. These grants will allow the development of phase I clinical trials including one marrow transplantation, gene therapies, and novel cytotoxic agents, with Johns Hopkins that can then be taken to ECOG for disease-specific phase II and phase III evaluation. New areas of Johns Hopkins involvement in ECOG include genitourinary and hematologic malignancies. Mechanisms are in place to bring innovative research projects in these 2 areas into ECOG. Accrual is expected to increased because of expanded clinical programs and faculty as we plan for a new larger Cancer Center at Johns Hopkins. In addition, a new director of Regional Programs has been appointed with the specific goal of expanding our hospital network to provide greater access to high priority ECOG/NCI sponsored trials including cancer control and prevention studies.